The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
SAN FRANCISCO, Oct 24 (Reuters) - IBM (IBM.N), opens new tab said on Friday it can run a key quantum computing error correction algorithm on commonly available chips ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
The White House has answered what had been one of the major outstanding questions regarding its pending deal to transfer TikTok’s US operations to a majority American ownership group: Under the ...
The modern internet is ruled by algorithms. When you boot up Instagram, for example, what you see in your feed is strategically sorted by the app's AI based on your past activity to keep you engaged ...
The original version of this story appeared in Quanta Magazine. One July afternoon in 2024, Ryan Williams set out to prove himself wrong. Two months had passed since he’d hit upon a startling ...
During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback